anti-TROP-2 antibody-drug conjugate DB-1305
Term · Oncology and biomedicine · MLC-T-ONC-011155
An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently linked, via a cleavable linker containing maleimide tetrapeptide, to the topoisomerase-1 inhibitor P1021, with potential antineoplastic activity. Upon administration of the anti-TROP-2 ADC DB-1305, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor P1021 is released, and inhibits DNA topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
| Identifier | MLC-T-ONC-011155 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | DITAC DB-1305; ADC DB-1305; anti-TROP-2 ADC DB-1305; anti-TROP-2/P1021 ADC DB-1305; anti-TROP-2/topoisomerase-1 inhibitor ADC DB-1305 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011155",
"term": "anti-TROP-2 antibody-drug conjugate DB-1305",
"field": "Oncology and biomedicine",
"definition": "An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently linked, via a cleavable linker containing maleimide tetrapeptide, to the topoisomerase-1 inhibitor P1021, with potential antineoplastic activity. Upon administration of the anti-TROP-2 ADC DB-1305, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor P1021 is released, and inhibits DNA topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.",
"synonyms": [
"DITAC DB-1305",
"ADC DB-1305",
"anti-TROP-2 ADC DB-1305",
"anti-TROP-2/P1021 ADC DB-1305",
"anti-TROP-2/topoisomerase-1 inhibitor ADC DB-1305"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-trop-2-antibody-drug-conjugate-db-1305/"
}
Record 2,302 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.